Health

Novel monoclonal antibody could help revolutionize treatment of children with





Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology.

Neuroblastoma is a cancer of immature nerve cells in the sympathetic nervous system. The tumor is diagnosed in about 700 individuals annually in the U.S., mostly children 5 years old or younger. Despite aggressive therapy, nearly half of patients with high-risk neuroblastoma die of their disease.

Results of a St. Jude phase II clinical trial reported significantly higher survival rates for newly diagnosed patients whose treatment included the humanized monoclonal antibody hu14.18K322A along with standard therapy for high-risk disease. Three-year disease-free survival was 73.7% for the 64 children enrolled in the study. The overall survival was 86%.

I have treated high-risk neuroblastoma for 30 years, and I have never seen results like this in high-risk patients. This is the best result published to date for patients with high-risk neuroblastoma, period.”

Wayne Furman, M.D., first and corresponding author, Department of Oncology, St. Jude Children’s Research Hospital

If the findings are confirmed in a larger, multi-center clinical trial, the chemoimmunotherapy detailed in this research could become standard treatment for patients with high-risk disease, Furman said.

An anti-GD2 monoclonal antibody with a difference

Hu14.18322A was designed in the laboratory to bind GD2 antibodies on the surface of neuroblastoma tumor cells. The binding rallies immune cells to attack and kill tumor cells. The monoclonal antibody used in this study was made at the Children’s GMP, LLC., on the St. Jude campus, using a process that was refined by scientists at the manufacturing facility.

Hu14.18322A is not the first monoclonal antibody designed for treatment of neuroblastoma. GD2 antibodies are found on some normal tissue, including cells in the peripheral nervous system. Unlike other anti-GD2 monoclonal antibodies, hu14.18322A is engineered to reduce dose-limiting pain and other treatment side effects.

The phase II study included hu14.18K322A throughout treatment. The therapy included high-dose chemotherapy, immunotherapy with granulocyte-macrophage colony-stimulating factor and interleukin 2, surgery, autologous blood stem cell transplantation and radiation. Patients also received opioids for pain management. Evidence from this and previous studies suggests that combining hu14.18K322A with the other immunotherapies and high-dose chemotherapy has a synergistic effect.

Is dose the key?

Dinutuximab was the first anti-GD2 monoclonal antibody approved by the U.S. Food and Drug Administration for treatment of high-risk neuroblastoma.

Patients in the St. Jude phase II clinical trial received significantly higher doses of hu14.18K322A, about 2.5 times more, than the maximum approved dose of dinutuximab.

“Since dinutuximab cannot be given at the same dose, one of the unanswered questions is whether the patient results in this study were so good because hu14.18K322A is a better antibody or because patients are receiving a higher dose,” Furman said.

Hu14.18K322A is owned by EMD Serono, a division of German-based Merck KGaA. The monoclonal antibody was developed for clinical use at St. Jude. The hu14.18K322A used in this trial was produced in the Children’s GMP, LLC, a facility on the St. Jude campus that produces biopharmaceuticals such as monoclonal antibodies under strict federal guidelines.

Source:

St. Jude Children’s Research Hospital

Read The Full Article Here

When Visitation Dreams Occur in Kids…
New Year’s Resolutions for Children
Isn’t it Funny How People Without Kids Try To Tell You How To Raise Yours?
The Best 4 Christmas Values to Teach our Kids
Prince Harry Opens Up About When He Knew Meghan Markle
Rich Pregnant vs Broke Pregnant
How To Watch The Perseid Meteor Shower With Your Family
10 Tips For PREGNANT Women
Baby Care Tips
How to Care a newborn kitten
Main Tota Hare Rang Ka
Drug Free Kids
When Visitation Dreams Occur in Kids…
New Year’s Resolutions for Children
Understanding Fears in Kids and Teens
The Clash of Two French Parenting Styles
When Visitation Dreams Occur in Kids…
Understanding Fears in Kids and Teens
Self-Mutilation In Teenagers. What to do?
My Child Is Afraid of Vomiting And This Creates A Lot Of Discomfort In Our lives!
Child Development: Are You Anxious About Autistic Risks?
Autism: Tools To Adapt Yourself To Your Child’s Emotions And Unexpressed Requests
Mindfulness with Your Kids
The Psychological Contents of Halloween
Quality Moments: Learn Navajo with your child!
DAYCARE SCHEDULE